West Nathan R, Panet-Raymond Valerie, Truong Pauline T, Alexander Cheryl, Babinszky Sindy, Milne Katy, Ross Louetta A, Loken Steven, Watson Peter H
Deeley Research Centre, Vancouver Island Cancer Centre, British Columbia Cancer Agency, 2410 Lee Avenue, Victoria, BC, Canada, V8R 6V5.
Breast Cancer (Auckl). 2011;5:105-15. doi: 10.4137/BCBCR.S7344. Epub 2011 May 31.
Ipsilateral breast tumor recurrence (IBTR) is an increasingly common clinical challenge. IBTRs include True Recurrences (TR; persistent disease) and New Primaries (NP; de novo tumors), but discrimination between these is difficult. We assessed tumor infiltrating leukocytes (TIL) as biomarkers for distinguishing these types of IBTR using primary tumors and matched IBTRs from 24 breast cancer patients, half of which were identified as putative TRs and half as NPs using a previously reported clinical algorithm. Intratumoral lymphocyte populations (CD3, CD8, CD4, CD25, FOXP3, TIA1, CD20) and macrophages (CD68) were quantified by immunohistochemistry in each tumor. Compared to matched primaries, TRs showed significant trends towards increased CD3(+) and CD8(+) TIL, while these populations were often diminished in NPs. Comparison of IBTRs showed that TRs had significantly higher levels of CD3(+) (P = 0.0136), CD8(+) (P = 0.0092), and CD25(+) (P = 0.0159) TIL than NPs. We conclude that TIL may be a novel diagnostic biomarker to distinguish NP from TR IBTRs.
同侧乳腺肿瘤复发（IBTR）是一个日益常见的临床挑战。IBTR包括真性复发（TR；持续性疾病）和新发原发性肿瘤（NP；新发肿瘤），但区分这两者很困难。我们使用来自24例乳腺癌患者的原发性肿瘤和匹配的IBTR，评估肿瘤浸润白细胞（TIL）作为区分这些类型IBTR的生物标志物，其中一半患者使用先前报道的临床算法被鉴定为假定的TR，另一半为NP。通过免疫组织化学对每个肿瘤中的瘤内淋巴细胞群体（CD3、CD8、CD4、CD25、FOXP3、TIA1、CD20）和巨噬细胞（CD68）进行定量。与匹配的原发性肿瘤相比，TR显示出CD3(+)和CD8(+) TIL增加的显著趋势，而这些群体在NP中往往减少。对IBTR的比较显示，TR的CD3(+)（P = 0.0136）、CD8(+)（P = 0.0092）和CD25(+)（P = 0.0159）TIL水平显著高于NP。我们得出结论，TIL可能是区分NP与TR IBTR的一种新型诊断生物标志物。
